ACG Engineering, a division of ACG, a leading supplier of integrated manufacturing solutions to the global pharmaceutical and nutraceutical industries, has launched its new SMARTCOATER X•ONE series, the company’s fastest tablet coater to date.
The SMARTCOATER X•ONE has been designed to make tablet coating extremely fast, with an extra emphasis on process speed, efficiency and operator ease. Its advanced baffle design ensures the quickest process times for batches from 10-100%.
Features of the new coater include a unique airflow pattern for optimised drying, a fully perforated coating drum, closed dust-free charging, integrated discharge baffles, active purging temperature sensor, a high-performing spray-arm and a 2.0 spray nozzle which has been developed with an anti-bearding cap. It also incorporates ACG’s X•ONE command and control system, designed to facilitate compliance with cGMP standards.
Rajesh Menon, Chief Technology Officer at ACG Engineering, remarked: "Our SMARTCOATER machines are already renowned for their innovative features and operator friendly designs. Now, after extensive research and development, we are excited to announce the launch of the X•ONE series.
"Our quality-commitment philosophy means that the new machine has been crafted to achieve maximum efficiency and flexibility for superior tablet coating, across every process – from charging to coating, discharging to cleaning. Each and every cycle is now swifter, more streamlined and profitable."
ACG Engineering launches the SMARTCOATER X ONE Series
The company's fastest tablet coater ensures optimised tablet coating
You may also like
Manufacturing
![Why your coating process is less consistent than you think - and what to do about it]()
Why your coating process is less consistent than you think - and what to do about it
Read moreTablet coating defects rarely begin at the coating stage. In this live webinar, industry expert Fred Rowley examines the upstream variables - suspension handling, spray-rate stability, gun pattern verification - that determine whether a coating process performs consistently at scale
Trending Articles
You may also like
Manufacturing
![Why your coating process is less consistent than you think - and what to do about it]()
Why your coating process is less consistent than you think - and what to do about it
Tablet coating defects rarely begin at the coating stage. In this live webinar, industry expert Fred Rowley examines the upstream variables - suspension handling, spray-rate stability, gun pattern verification - that determine whether a coating process performs consistently at scale
Manufacturing
![Meet the modern tablet coater designed to tackle your coating challenges]()
Meet the modern tablet coater designed to tackle your coating challenges
The pharmaceutical industry has witnessed incredible technological advancements over the years, with tablet-coating technology being no exception. What began as a simple effort to enhance the aesthetic appeal and palatability of tablets has evolved into a sophisticated process that plays a critical role in drug delivery
Manufacturing
![ACG brings patient-friendly access and ultra-high barrier protection together in blister packaging]()
ACG brings patient-friendly access and ultra-high barrier protection together in blister packaging
ACG’s CR/SF lidding foil and Ultrasafe thermoformable film address two critical blister-packaging requirements: making individual doses accessible to intended users while protecting formulations from oxygen and moisture
Manufacturing
![How the EU PPWR shifts blister packaging decisions upstream]()
How the EU PPWR shifts blister packaging decisions upstream
The difference in moisture permeation of pharmaceutical blister packaging materials can be as wide as 259-fold.(1) Historically, the cost of over-specifying packaging was limited to higher material costs. Now, the EU’s PPWR framework is set to increase the long-term cost of excess barrier material. However, determining the optimal specification is not solely a packaging decision. This blog outlines how formulation, process development and packaging operations can converge to optimise drug product stability while reducing future EPR costs